Emma L. Culver

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Obexelimab for the Treatment of IgG4-Related Disease.

Obexelimab for the Treatment of IgG4-Related Disease.

Journal: The New England journal of medicine

Published: June 03, 2026

Making space and opportunities for talent to grow.

Making space and opportunities for talent to grow.

Journal: JHEP reports : innovation in hepatology

Published: May 14, 2026

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.

Journal: BMJ open

Published: March 11, 2026

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Journal: Nature reviews. Gastroenterology & hepatology

Published: February 19, 2026

Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.

Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.

Journal: Rheumatology and therapy

Published: December 22, 2025

Enhancing liver fibrosis measurement: Deep learning and uncertainty analysis across multi-center cohorts.

Enhancing liver fibrosis measurement: Deep learning and uncertainty analysis across multi-center cohorts.

Journal: Journal of pathology informatics

Published: December 12, 2025

Periductal iron-corrected T1 is a predictor of adverse outcomes in large-duct primary sclerosing cholangitis.

Periductal iron-corrected T1 is a predictor of adverse outcomes in large-duct primary sclerosing cholangitis.

Journal: BMC medical imaging

Published: November 25, 2025

Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis.

Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis.

Journal: JHEP reports : innovation in hepatology

Published: November 05, 2025

Clinical Updates in IgG4-Related Pancreatic and Hepatobiliary Disease.

Clinical Updates in IgG4-Related Pancreatic and Hepatobiliary Disease.

Journal: British journal of hospital medicine (London, England : 2005)

Published: September 30, 2025

The Prognostic Utility of Quantitative Magnetic Resonance Cholangiopancreatography in Patients With PSC: A Systematic Review With Structured Evidence Synthesis.

The Prognostic Utility of Quantitative Magnetic Resonance Cholangiopancreatography in Patients With PSC: A Systematic Review With Structured Evidence Synthesis.

Journal: Journal of computer assisted tomography

Published: July 14, 2025

Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model.

Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: June 09, 2025

Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study.

Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study.

Journal: Hepatology (Baltimore, Md.)

Published: May 24, 2025

Showing 1-12 of 87

Last Updated: 09/26/2026